: Estimates of variance explained using GCTA. Table 4 : Estimating inflation due to genotyping errors. Table 5 : Variance explained by previously reported susceptibility loci. Table 6 : Expected success of marginal (single-SNP) analyses. In linear regression, the estimated regression coefficient is β = Cov(X, Y )/Var(X), where X denotes the genotypic values of the SNP being tested and Y the phenotypic values. For simplicity, suppose both X and Y have been centred and scaled to have mean zero and variance one. For a binary phenotype comprising n A cases and n U controls, Y will take value Y A = n U /n A if a case, and Y U = − n A /n U if a control. Therefore,
where n = n A + n U , and M A and M U are the mean values of X across cases and controls, respectively. The proportion of phenotypic variation explained by this SNP will be β 2 = n A n A (M A − M U ) 2 /n 2 , and so the important value is S = M A − M U , the mean difference in genotypic values between cases and controls. Although, strictly speaking, logistic regression would be more appropriate, for small effect sizes, this linear approximation will suffice. Now suppose that out of the n U controls, a proportion p are actually cases, and consider the effect on S. The mean genotypic value for cases will continue to be M A , but the controls will now have mean (1 − p)M U + pM A , and the observed difference will be S = (1 − p)(M A − M U ). Therefore, each SNP will (on average) contribute only (1 − p) 2 as much heritability as it would if cases and controls were correctly labelled, so summed over all SNPs, the estimate of total SNP heritability will also be lower by this fraction. Supplementary Fig. 8 demonstrates this relationship holds for values of p up to 0.25. If, additionally, p cases are wrongly labelled as controls, then similar calculations demonstrate the heritability will be lower by (1 − p − p ) 2 .
Note 2: Inflation due to genotyping errors.
When the n U control samples come from two datasets, of sizes n 1 and n 2 , we show that the estimate of total variance explained can be written as
where T denotes the true variance explained, while G1 and G2 correspond to inflation due to genotyping errors within Control Datasets 1 and 2, respectively.
Suppose that for SNP X, the true difference in mean genotypic values between cases and controls is S = M A − M U , and so as shown in Supplementary Note 1, the proportion of phenotypic variance the SNP explains is n A n A S 2 /n 2 . If A 1 and A 2 denote the amounts by which genotyping errors within each control dataset increase the mean value of X for each dataset, then M U will be increased by
and as a result the variance explained by the SNP now equals
If two centred random variables, U and V , are independent, then E((U − V ) 2 ) = E(U 2 ) + E(V 2 ). Therefore, if we suppose that, for any given SNP, the values of S, A 1 and A 2 are independent and have mean zero (which seems reasonable, especially considering that with relatively few SNPs causal and accurate genotyping, we would expect most values to be zero), then we can write the total heritability in the form given by (1) where T , G 1 and G 2 are the sums across all SNPs of S 2 , A Figure S1 . Estimating inflation due to cryptic relatedness. To estimate the extent by which residual familial relatedness and population structure inflates estimates of heritability, we calculate heritability from Chromosomes 1-8, then from Chromosomes 9-22, and from the sum of these two estimates subtract the estimate of heritability from all autosomes. The x-axis indicates the number of principal component axes included in the regression model, the y-axes reports the estimate of inflation (values correspond to the liability scale and are in absolute terms). These tests indicate there is little benefit including more than five principal component axes as fixed effect covariates (red boxes), at which point the estimated inflation is 2.8% for all epilepsy, 2.5% for focal epilepsy and 0.4% for non-focal epilepsy; in relative terms, these values represent 9%, 8% and 1% of the estimate of h Figure S2 . Power for marginal (single-SNP) analyses. The test statistic from standard linear regression has a χ 2 distribution with non-centrality parameter nh 2 /(1 − h 2 ), where n is the sample size and h 2 is the proportion of phenotypic variance explained by the SNP. For a binary trait, h 2 corresponds to the observed scale (cases 1, controls 0), but knowing the disease prevalence and study ascertainment, it can be converted to the liability scale using the transformation detailed in Figure S5 . The three plots correspond to the phenotypes all epilepsy (1258 cases, 5129 controls), focal epilepsy (958 cases) and non-focal epilepsy (300 cases). In each plot, the y-axis shows how the probability that a SNP achieves genome-wide significance (5 × 10 −8 ) depends on the proportion of liability variance it explains (x-axis). The red and green lines mark the thresholds for 50% and 80% detection power. Figure S3 . Marginal (single-SNP) association analyses. Each plot reports −log 10 p-values from marginal tests of association, where red/green points correspond to genotyped SNPs and grey to imputed. From top to bottom, the plots refer to all epilepsy (1258 cases, 5129 controls), focal epilepsy (958 cases), non-focal epilepsy (300 cases) and generalized epilepsy (151 cases). The conventional threshold for genome-wide significance (5×10 −8 ) is marked in each plot by a horizontal dashed line. Figure S4 . The liability model for diseases. When considering binary outcomes, it is convenient to assume an underlying liability model, whereby case/control status is determined by whether an unobserved random variable (the "liability") is above or below a threshold value, T . The liability is assumed to have a standard normal distribution, so T is determined by the prevalence of the disease K: the area to the right of T must equal K (e.g., for all epilepsy, K = 0.005 so T = 2.58). z is the height of the standard normal curve at the threshold. 
where K is the prevalence, p the proportion of cases in the sample and z is the standard normal density at the liability threshold. To test the reliability of this transformation for our analysis, we constructed a population dataset consisting of 280 000 individuals genotyped for 20 000 independent SNPs. We generated liability values with heritability 0.1, 0.2, 0.3 or 0.4, supposing 2000 SNPs were causal; individuals with liability > Φ −1 (0.995), were deemed cases, the remainder controls (Φ is the standard normal cumulative density function). From this population dataset, we selected at random 1258 cases and 5129 controls, using which we estimated heritability. On average, estimate of h Figure S6 . Estimating inflation due to genotyping errors; proof of principle. For this simulation, we used (pre-imputation) genotypes for Chromosomes 1 and 2 (40 032 SNPs) and all 6387 individuals. We generated liability values with 50% heritability supposing 2000 SNPs were causal; individuals with liability > Φ −1 (0.6), became cases, the remainder controls. We first computed a kinship matrix using the observed genotypes, from which we obtained a "correct" estimate of h 2 O . In order to simulate genotyping errors, we randomly divided the control individuals into two sets. For 5% of SNPs, we picked a random error term (drawn from a uniform distribution on [-0.05,0 .05]), and added this value to genotypes for individuals within the first control dataset. We did the same for individuals within the second control dataset (again affecting 5% of SNPs). We then recomputed kinships and obtained a new estimate of h 2 O ; the difference between this and the correct estimate represents the "true" inflation due to genotyping errors. We also considered increasing the proportion of affected SNPs to 10% and 15%, and repeated the process for a total of 10 phenotypes. For each phenotype, the left plot shows how well we can estimate the inflation due to genotyping errors using the method outlined in the main text. The right plot presents unadjusted (red) and adjusted (green) estimates of h 2 O (all values are relative to the correct estimates). We see that even when genotyping errors more than double the estimate of h 2 O , we can still expect to recover the correct estimate with reasonable accuracy. Figure S7 . Estimating the number of causal variants. In the main text, we focus on estimating the number of causal variants for the phenotype all epilepsy. Here, we also consider the subtypes focal and non-focal epilepsy. We vary the number of causal variants (x-axis) and the assumed distribution of heritability across these variants (black, equal; red, uniform; green, exponential; blue, chi squared), with parameters chosen to ensure the total variance explained by causal variants matches our estimates based on the real data; for these simulations, the y-axis reports the probability that in marginal tests of association, no SNP exceeds the lowest p-value observed for the real data. For each distribution, our point estimate (lower bound) for the number of causal variants is the number required for this probability to exceed 0.5 (0.05). These estimates are marked by vertical lines. Figure S9 . The effect of mislabelling samples; proof of principle. Given that a fraction p of controls are in fact cases, we calculate that the estimate of h
2 times the true value. We test this theory through simulation, using (pre-imputation) genotypes for Chromosomes 1 and 2 (40 032 SNPs) and all 6387 individuals. We first generated liability values with 50% heritability supposing 2000 SNPs were causal, according to which we dichotomised individuals into cases and controls based on a threshold of 0. The "correct" heritability estimate is that obtained using the correct labellings. Then we randomly sample 5% of cases, relabel these as controls and re-estimate heritability, recording the average heritability over ten samplings (measured as a proportion of the correct estimate). We also consider 10%, 15%, 20% and 25% of cases wrongly labelled, and repeat for a total of 50 phenotypes. We find that the observed proportions closely concentrate around those expected (dashed line). Figure S10 . Principal component plot of samples. The x and y-axes correspond to the first two axes from principal component analysis. After checks of genotyping accuracy, and removal of individuals so that no pair remained with estimated kinship > 0.1875, (a level of relatedness halfway between those expected for full-sibs and cousins), 6561 samples remained. Then 36 were excluded as suspected population outliers (grey) and 83 to remove pairwise relatedness higher than that expected by chance (purple). Of the remaining samples, 5129 were controls (black) and 1295 cases, of which 958 had type focal (red), 151 generalized (green), 149 unclassified (dark blue) and 40 had status unknown (light blue). Table S1 . Phenotypic breakdown of epilepsy cases. All epilepsy cases were carefully phenotyped by epilepsy specialists (see [1] for details). Clinical data included: numbers and types of epilepsy seizures pre-treatment, results of MRI and EEG, information on drug treatment and outcome. Most patients were reviewed on at least ten occasions post starting treatment, and all patients were re-evaluated at data entry to confirm accuracy of seizure and epilepsy classification. From this information it was possible to identify subsets of individuals exhibiting specific epilepsy subtypes, some of which are listed above. However, to ensure reasonable sample size we focused analysis on three broad phenotypes: all epilepsy, focal epilepsy and non-focal epilepsy. Table S3 . Estimates of variance explained using GCTA. For the estimates of h 2 L in the main text, we computed a weighted kinship matrix using LDAK [2] which allows for the uneven nature of linkage disequilibrium. Here we report estimates when we omit this adjustment and instead follow the procedure of GCTA, [3] which weights each SNP equally when computing the kinship matrix. We would expect an estimate based on imputed SNPs to be no smaller than that based on genotyped SNPs, but we see that without adjusting for uneven tagging, this proves not to be the case. As before, h Table S5 . Variance explained by previously reported susceptibility loci. We first estimate the variance explained on the liability scale h 2 L (standard deviation in parenthesis) by the 6003 SNPs within 500 kb of the three loci previously identified through genome-wide association studies: rs2292096 (located at 1q32.1), rs13026414 (2p16.1) and rs72823592 (17q21.32). Next we consider the 119 630 SNPs located inside or within 20 kb of 85 genes obtained by searching the UniProtKB database (http://www.uniprot.org) using the keyword "epilepsy". The first p-value corresponds to a "self-contained" test that the estimate of variance explained is significantly greater than zero. For the susceptibility genes, we additionally provide a p-value for a "competitive test" which assesses whether the 119 630 SNPs explain more variance than expected given the total variance explained by all SNPs. For this we use cyclic permutations to obtain 500 new lists of 119 630 SNPs displaying similar structure to the original list; for each permutation, we increase the SNP index by 2500 (so if the original list contains SNPs 1, 2, 3, ..., the first permutation will consider SNPs 2501, 2502, 2503, ...). Permuted P 1 indicates how often a permutation resulted in a larger estimate of h 2 L ; Permuted P 2 indicates how often a permutation resulted in a smaller P h 2 L >0 . Table S6 . Expected success of marginal (single-SNP) analyses. Our dataset had sample size n = 6387. Considering four distributions of heritability across causal loci, in each case supposing our point estimate for the number of causal variants is correct, we predict how the success of future genome-wide association studies will improve by increasing n. We also consider if the case-control ratio (currently 1258:5129) was instead increased to 1:2. Table S7 . Bivariate analysis for focal and non-focal epilepsy. GCTA can estimate the correlation ρ between effect sizes for pairs of traits (here, two subtypes of epilepsy). To perform the test, it is necessary to pair each of the two sets of cases (here, focal or non-focal patients) with a control dataset (either National Blood Service or 1958 Birth Cohort), so we consider both possible combinations. We report the estimate of ρ (standard deviation in parentheses), P from a test that the two traits have identical genetic architectures (ρ = 1) and P from a test that the genetic architectures have no shared component (ρ = 0). In the main text, we report the average correlations and p-values across the two combinations.
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